Global Market Access Strategy for a New Oncology Therapy Launch with a Focus on the Asia-Pacific and New Market Regions

A large pharmaceutical company was preparing to launch a next-generation oncology therapy across a range of indications in a diverse set of markets in the Asia-Pac region and in other new market areas. It faced a highly competitive market and needed a comprehensive market access strategy.

To inform this global strategy, we assessed the therapy’s value, access, and pricing opportunities and risks, accounting for evidence, competitor precedents, and payer/access channels. The access strategy would cut across multiple indications, including prioritization and sequencing, providing indication-specific strategies and considerations in prioritized markets. It would also identify key global access initiatives. The project involved three key phases: A broad opportunity and risk assessment, the strategy development phase, and finally, the tactical planning and execution phase.

As a result of our work, which spanned multiple project engagements, the client was well-prepared for launch across its priority markets. It’s interactions with payers (and the launch overall) were successful.